CE-6
Monotherapy
Assessment of Ranolazine In Stable Angina
MARISA (CVT 3031)
MARISA (CVT 3031)
§Patients withdrawn
from other anti-anginals
(N = 191 randomized)
(N = 191 randomized)
§Randomized, double-blind,
4-period crossover
–1-wk treatment periods
–Placebo vs 500, 1000, and 1500 mg bid
§Exercise tests after each
week of treatment
–At trough (12 hr after
dosing)
–At peak (4 hr after dosing)